Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy

Background To assess correlation of pretreatment specific growth rate (SGR) value of 0.43 × 10‐2 with overall and failure‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Methods A retrospective chart review of 160...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2021-01, Vol.12 (2), p.201-209
Main Authors: Atallah, Soha, Le, Lisa W., Bezjak, Andrea, MacRae, Robert, Hope, Andrew J., Pantarotto, Jason
Format: Article
Language:English
Subjects:
Biopsy
Cancer therapies
Failure
Gender
Growth rate
Lung cancer
Medical prognosis
Original
predictive model
Radiation therapy
SBRT
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3
cites cdi_FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3
container_end_page 209
container_issue 2
container_start_page 201
container_title Thoracic cancer
container_volume 12
creator Atallah, Soha
Le, Lisa W.
Bezjak, Andrea
MacRae, Robert
Hope, Andrew J.
Pantarotto, Jason
description Background To assess correlation of pretreatment specific growth rate (SGR) value of 0.43 × 10‐2 with overall and failure‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Methods A retrospective chart review of 160 patients with pathologically confirmed stage I NSCLC treated with SBRT between June 2010 and December 2012 in a large, tertiary cancer institute was undertaken. Both diagnostic and archived planning CT were uploaded to the treatment planning system to determine tumor volume at diagnosis (GTV1) and planning time (GTV2). The time (t) between both CTs was recorded. SGR was calculated using GTV1, GTV2, and t. The median SGR (0.43 × 10‐2) from our previous data was used to group patients into low and high SGR cohorts. Log‐rank test was used to compare overall (OS) and failure‐free survivals (FFS) of SGR groups. Results The median time interval between diagnostic and planning CT scans was 87 days. The median OS was 38 and 66 months for high and low SGR cohorts, respectively (P = 0.03). The median FFS was 27 and 55 months for high and low SGR cohorts, respectively (P = 0.005). High SGR (P 
doi_str_mv 10.1111/1759-7714.13744
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7812066</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478392276</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3</originalsourceid><addsrcrecordid>eNqFkc1O3DAUhS1EBYiy7q6yxHrAv3GyQUIjaCshsYFuLce5mTFK4tRxGGXHA7DgGfskdRg6ghV3Y8s-9zv36iD0jZIzmuqcKlkslKLijHIlxB462r3s7-4kO0Qnw_BAUvG8IEweoEPOmcw5oUfo-bdpXGWi61bYtb2xEfsa9wFiABNb6CKOY-sDXgW_iWscTATsO-zHaH0LsxhMaKa_Ty9DNCvAzZhI1nQWAn5lQIU3LnUOEQL4mBycxaWvpsSqXHJOtLiGYPrpK_pSm2aAk7fzGN1fX90tfy5ubn_8Wl7eLKzIlFhQaWhdFkwwy0uV15JIKypLqMhzyqoyM0QJWXEQNu0s65owklkLqgaRFcbyY3Sx5fZj2UJl05bBNLoPrjVh0t44_fGnc2u98o9aJT7JsgQ4fQME_2eEIeoHP4YuzayZUDkvGFOz6nyrssEPQ4B650CJnhPUc0Z6zku_Jpg6vr8fbKf_n1cSyK1g4xqYPuPpu-XlFvwPygSqYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478392276</pqid></control><display><type>article</type><title>Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy</title><source>Publicly Available Content (ProQuest)</source><source>PubMed</source><source>Wiley Open Access</source><creator>Atallah, Soha ; Le, Lisa W. ; Bezjak, Andrea ; MacRae, Robert ; Hope, Andrew J. ; Pantarotto, Jason</creator><creatorcontrib>Atallah, Soha ; Le, Lisa W. ; Bezjak, Andrea ; MacRae, Robert ; Hope, Andrew J. ; Pantarotto, Jason</creatorcontrib><description>Background To assess correlation of pretreatment specific growth rate (SGR) value of 0.43 × 10‐2 with overall and failure‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Methods A retrospective chart review of 160 patients with pathologically confirmed stage I NSCLC treated with SBRT between June 2010 and December 2012 in a large, tertiary cancer institute was undertaken. Both diagnostic and archived planning CT were uploaded to the treatment planning system to determine tumor volume at diagnosis (GTV1) and planning time (GTV2). The time (t) between both CTs was recorded. SGR was calculated using GTV1, GTV2, and t. The median SGR (0.43 × 10‐2) from our previous data was used to group patients into low and high SGR cohorts. Log‐rank test was used to compare overall (OS) and failure‐free survivals (FFS) of SGR groups. Results The median time interval between diagnostic and planning CT scans was 87 days. The median OS was 38 and 66 months for high and low SGR cohorts, respectively (P = 0.03). The median FFS was 27 and 55 months for high and low SGR cohorts, respectively (P = 0.005). High SGR (P &lt; 0.05), male gender (P = &lt;0.01), and GTV2 (P = &lt;0.05) were associated with poorer FFS. Conclusions High SGR was associated with poorer outcome in patients with early‐stage NSCLC treated with SBRT. SGR can be used in conjunction with other well‐known predictive factors to formulate a practical predictive model to identify subgroups of the patient at higher risk of recurrence after SBRT. We demonstrated that tumor growth rate (GR) predicts treatment outcome in early‐stage lung cancer patients treated with SBRT. We used specific growth rate (SGR) as a metric for pretreatment GR and its median (0.43 × 10‐2) to group patients into high and low SGR cohorts. In this study, the same median SGR was validated in an independent dataset at a different cancer institution. Patients with high SGR tumors consistently had significantly lower survival and higher regional failure.</description><identifier>ISSN: 1759-7706</identifier><identifier>EISSN: 1759-7714</identifier><identifier>DOI: 10.1111/1759-7714.13744</identifier><identifier>PMID: 33258301</identifier><language>eng</language><publisher>Melbourne: John Wiley &amp; Sons Australia, Ltd</publisher><subject>Biopsy ; Cancer therapies ; Failure ; Gender ; Growth rate ; Lung cancer ; Medical prognosis ; Original ; predictive model ; Radiation therapy ; SBRT ; Tumors</subject><ispartof>Thoracic cancer, 2021-01, Vol.12 (2), p.201-209</ispartof><rights>2020 The Authors. published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd.</rights><rights>2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3</citedby><cites>FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3</cites><orcidid>0000-0001-6802-6790 ; 0000-0001-6793-2863</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2478392276/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2478392276?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33258301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atallah, Soha</creatorcontrib><creatorcontrib>Le, Lisa W.</creatorcontrib><creatorcontrib>Bezjak, Andrea</creatorcontrib><creatorcontrib>MacRae, Robert</creatorcontrib><creatorcontrib>Hope, Andrew J.</creatorcontrib><creatorcontrib>Pantarotto, Jason</creatorcontrib><title>Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy</title><title>Thoracic cancer</title><addtitle>Thorac Cancer</addtitle><description>Background To assess correlation of pretreatment specific growth rate (SGR) value of 0.43 × 10‐2 with overall and failure‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Methods A retrospective chart review of 160 patients with pathologically confirmed stage I NSCLC treated with SBRT between June 2010 and December 2012 in a large, tertiary cancer institute was undertaken. Both diagnostic and archived planning CT were uploaded to the treatment planning system to determine tumor volume at diagnosis (GTV1) and planning time (GTV2). The time (t) between both CTs was recorded. SGR was calculated using GTV1, GTV2, and t. The median SGR (0.43 × 10‐2) from our previous data was used to group patients into low and high SGR cohorts. Log‐rank test was used to compare overall (OS) and failure‐free survivals (FFS) of SGR groups. Results The median time interval between diagnostic and planning CT scans was 87 days. The median OS was 38 and 66 months for high and low SGR cohorts, respectively (P = 0.03). The median FFS was 27 and 55 months for high and low SGR cohorts, respectively (P = 0.005). High SGR (P &lt; 0.05), male gender (P = &lt;0.01), and GTV2 (P = &lt;0.05) were associated with poorer FFS. Conclusions High SGR was associated with poorer outcome in patients with early‐stage NSCLC treated with SBRT. SGR can be used in conjunction with other well‐known predictive factors to formulate a practical predictive model to identify subgroups of the patient at higher risk of recurrence after SBRT. We demonstrated that tumor growth rate (GR) predicts treatment outcome in early‐stage lung cancer patients treated with SBRT. We used specific growth rate (SGR) as a metric for pretreatment GR and its median (0.43 × 10‐2) to group patients into high and low SGR cohorts. In this study, the same median SGR was validated in an independent dataset at a different cancer institution. Patients with high SGR tumors consistently had significantly lower survival and higher regional failure.</description><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Failure</subject><subject>Gender</subject><subject>Growth rate</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Original</subject><subject>predictive model</subject><subject>Radiation therapy</subject><subject>SBRT</subject><subject>Tumors</subject><issn>1759-7706</issn><issn>1759-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNqFkc1O3DAUhS1EBYiy7q6yxHrAv3GyQUIjaCshsYFuLce5mTFK4tRxGGXHA7DgGfskdRg6ghV3Y8s-9zv36iD0jZIzmuqcKlkslKLijHIlxB462r3s7-4kO0Qnw_BAUvG8IEweoEPOmcw5oUfo-bdpXGWi61bYtb2xEfsa9wFiABNb6CKOY-sDXgW_iWscTATsO-zHaH0LsxhMaKa_Ty9DNCvAzZhI1nQWAn5lQIU3LnUOEQL4mBycxaWvpsSqXHJOtLiGYPrpK_pSm2aAk7fzGN1fX90tfy5ubn_8Wl7eLKzIlFhQaWhdFkwwy0uV15JIKypLqMhzyqoyM0QJWXEQNu0s65owklkLqgaRFcbyY3Sx5fZj2UJl05bBNLoPrjVh0t44_fGnc2u98o9aJT7JsgQ4fQME_2eEIeoHP4YuzayZUDkvGFOz6nyrssEPQ4B650CJnhPUc0Z6zku_Jpg6vr8fbKf_n1cSyK1g4xqYPuPpu-XlFvwPygSqYg</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Atallah, Soha</creator><creator>Le, Lisa W.</creator><creator>Bezjak, Andrea</creator><creator>MacRae, Robert</creator><creator>Hope, Andrew J.</creator><creator>Pantarotto, Jason</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>John Wiley &amp; Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6802-6790</orcidid><orcidid>https://orcid.org/0000-0001-6793-2863</orcidid></search><sort><creationdate>202101</creationdate><title>Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy</title><author>Atallah, Soha ; Le, Lisa W. ; Bezjak, Andrea ; MacRae, Robert ; Hope, Andrew J. ; Pantarotto, Jason</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Failure</topic><topic>Gender</topic><topic>Growth rate</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Original</topic><topic>predictive model</topic><topic>Radiation therapy</topic><topic>SBRT</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atallah, Soha</creatorcontrib><creatorcontrib>Le, Lisa W.</creatorcontrib><creatorcontrib>Bezjak, Andrea</creatorcontrib><creatorcontrib>MacRae, Robert</creatorcontrib><creatorcontrib>Hope, Andrew J.</creatorcontrib><creatorcontrib>Pantarotto, Jason</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley-Blackwell Open Access Backfiles (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thoracic cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atallah, Soha</au><au>Le, Lisa W.</au><au>Bezjak, Andrea</au><au>MacRae, Robert</au><au>Hope, Andrew J.</au><au>Pantarotto, Jason</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy</atitle><jtitle>Thoracic cancer</jtitle><addtitle>Thorac Cancer</addtitle><date>2021-01</date><risdate>2021</risdate><volume>12</volume><issue>2</issue><spage>201</spage><epage>209</epage><pages>201-209</pages><issn>1759-7706</issn><eissn>1759-7714</eissn><abstract>Background To assess correlation of pretreatment specific growth rate (SGR) value of 0.43 × 10‐2 with overall and failure‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Methods A retrospective chart review of 160 patients with pathologically confirmed stage I NSCLC treated with SBRT between June 2010 and December 2012 in a large, tertiary cancer institute was undertaken. Both diagnostic and archived planning CT were uploaded to the treatment planning system to determine tumor volume at diagnosis (GTV1) and planning time (GTV2). The time (t) between both CTs was recorded. SGR was calculated using GTV1, GTV2, and t. The median SGR (0.43 × 10‐2) from our previous data was used to group patients into low and high SGR cohorts. Log‐rank test was used to compare overall (OS) and failure‐free survivals (FFS) of SGR groups. Results The median time interval between diagnostic and planning CT scans was 87 days. The median OS was 38 and 66 months for high and low SGR cohorts, respectively (P = 0.03). The median FFS was 27 and 55 months for high and low SGR cohorts, respectively (P = 0.005). High SGR (P &lt; 0.05), male gender (P = &lt;0.01), and GTV2 (P = &lt;0.05) were associated with poorer FFS. Conclusions High SGR was associated with poorer outcome in patients with early‐stage NSCLC treated with SBRT. SGR can be used in conjunction with other well‐known predictive factors to formulate a practical predictive model to identify subgroups of the patient at higher risk of recurrence after SBRT. We demonstrated that tumor growth rate (GR) predicts treatment outcome in early‐stage lung cancer patients treated with SBRT. We used specific growth rate (SGR) as a metric for pretreatment GR and its median (0.43 × 10‐2) to group patients into high and low SGR cohorts. In this study, the same median SGR was validated in an independent dataset at a different cancer institution. Patients with high SGR tumors consistently had significantly lower survival and higher regional failure.</abstract><cop>Melbourne</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>33258301</pmid><doi>10.1111/1759-7714.13744</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6802-6790</orcidid><orcidid>https://orcid.org/0000-0001-6793-2863</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1759-7706
ispartof Thoracic cancer, 2021-01, Vol.12 (2), p.201-209
issn 1759-7706
1759-7714
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7812066
source Publicly Available Content (ProQuest); PubMed; Wiley Open Access
subjects Biopsy
Cancer therapies
Failure
Gender
Growth rate
Lung cancer
Medical prognosis
Original
predictive model
Radiation therapy
SBRT
Tumors
title Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validating%20impact%20of%20pretreatment%20tumor%20growth%20rate%20on%20outcome%20of%20early%E2%80%90stage%20lung%20cancer%20treated%20with%20stereotactic%20body%20radiation%20therapy&rft.jtitle=Thoracic%20cancer&rft.au=Atallah,%20Soha&rft.date=2021-01&rft.volume=12&rft.issue=2&rft.spage=201&rft.epage=209&rft.pages=201-209&rft.issn=1759-7706&rft.eissn=1759-7714&rft_id=info:doi/10.1111/1759-7714.13744&rft_dat=%3Cproquest_pubme%3E2478392276%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4674-15a1fb9242c3b78f505c4dc0148812db6a0745d3e4c0035ff0206cce7fe469ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2478392276&rft_id=info:pmid/33258301&rfr_iscdi=true